Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

NeuroPace (NPCE) EBIT (2020 - 2025)

NeuroPace has reported EBIT over the past 6 years, most recently at -$1.8 million for Q4 2025.

  • Quarterly results put EBIT at -$1.8 million for Q4 2025, up 51.63% from a year ago — trailing twelve months through Dec 2025 was -$16.3 million (up 24.61% YoY), and the annual figure for FY2025 was -$16.3 million, up 24.61%.
  • EBIT for Q4 2025 was -$1.8 million at NeuroPace, up from -$2.6 million in the prior quarter.
  • Over the last five years, EBIT for NPCE hit a ceiling of -$1.8 million in Q4 2025 and a floor of -$11.0 million in Q2 2022.
  • Median EBIT over the past 5 years was -$6.2 million (2021), compared with a mean of -$6.5 million.
  • Biggest five-year swings in EBIT: tumbled 435.42% in 2021 and later soared 51.63% in 2025.
  • NeuroPace's EBIT stood at -$9.0 million in 2021, then decreased by 9.36% to -$9.9 million in 2022, then surged by 48.77% to -$5.1 million in 2023, then rose by 27.68% to -$3.7 million in 2024, then soared by 51.63% to -$1.8 million in 2025.
  • The last three reported values for EBIT were -$1.8 million (Q4 2025), -$2.6 million (Q3 2025), and -$6.8 million (Q2 2025) per Business Quant data.